An Audit Strategy for Progression-Free Survival

Biometrics

Volumn 67, Issue 3, 2011, Pages 1092-1099

  Dodd, Lori E ^a   Korn, Edward L ^b   Freidlin, Boris ^b   Gray, Robert ^c   Bhattacharya, Suman ^d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d GENENTECH INC   (United States)

Author keywords

Auxiliary variables; Blinded independent central review; Event adjudication committee; Measurement error; Randomized clinical trial; Regression estimator

Indexed keywords

EFFICIENCY; HAZARDS; MEDICAL APPLICATIONS; PATIENT TREATMENT;

'CURRENT; AUXILIARY VARIABLES; BLINDED INDEPENDENT CENTRAL REVIEW; EVENT ADJUDICATION COMMITTEE; HAZARD RATIO; IMAGE INTERPRETATION; PROGRESSION FREE SURVIVAL; RANDOMIZED CLINICAL TRIALS; REGRESSION ESTIMATORS; TREATMENT EFFECTS;

ONCOLOGY;

CANCER; CORRELATION; DISEASE TREATMENT; ERROR ANALYSIS; MEASUREMENT METHOD; NUMERICAL MODEL; REGRESSION ANALYSIS;

EID: 80051679611     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2010.01539.x     Document Type: Article

References (16)

1. Cochran, W. G. (1977). Sampling Techniques, 3rd edition. New York: John Wiley and Sons.
2. Dodd, L. E., Korn, E. L., Freidlin, B., Jaffe, C. C., Rubinstein, L. V., Dancey, J., and Mooney, M. M. (2008). Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense Journal of Clinical Oncology 26, 3791-3796.
3. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubenstein, L., Dodd, L., Kaplan, R., Lacombe, D., and Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45, 228-247.
4. EMEA. (2008). Methodological considerations for using progression-free survival (PFS) as primary endpoint in confirmatory trials for registration.
5. FDA. (2007). Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics.
6. Gray, R., Bhattacharya, S., Bowden, C., Miller, K., and Comis, R. L. (2009). Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. Journal of Clinical Oncology 27, 4966-4972.
7. Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800-802.
8. Hsu, C., Taylor, J. M. G., and Murray, S. (2006). Survival analysis using auxiliary variables via non-parametric multiple imputation. Statistics in Medicine 25, 769-781.
9. Kaplan, R. S. (1973). Statistical sampling in auditing with auxiliary information estimators. Journal of Accounting Research 11, 238-258.
10. Korn, E. L. and Graubard, B. I. (1999). Analysis of Health Surveys. New York: Wiley-Interscience.
11. Korn, E. L., Dodd L. E., and Freidlin, B. (2010). Measurement error in survival analyses in RCTs. Clinical Trials7, 626-633.
12. Lu, X. and Tsiatis, A. A. (2008). Improving the efficiency of the log-rank test using auxiliary covariates. Biometrika 95, 679-694.
13. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., and Davidson, N. E. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine 357, 2666-2676.
14. Pepe, M. S., Reilly, M., and Fleming, T. R. (1994). Auxiliary outcome data and the mean score method. Journal of Statistical Planning and Inference 42, 137-160.
15. Robins, J. and Finkelstein, D. (2000). Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56, 779-788.
16. Ruan, P. K. and Gray, R. J. (2008). Sensitivity analysis of progression-free survival with dependent withdrawal. Statistics in Medicine 27, 1180-1198.